/PRNewswire/ Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their.
/PRNewswire/ Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months.
/PRNewswire/ Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months.
/PRNewswire/ Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months.
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
There are approximately 160,000 patients in the U.S. living with eosinophilic. | April 4, 2022